At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glucose Control Using 1,5-AG: Randomized Controlled Trial
In Brief
A clinical study evaluating GlycoMark 1-5-AG and Clinical Performance and Value Vignettes for Diabetes. Completed, enrolled 156 participants across 1 site.
Detailed Summary
Glycemic excursions (temporary increases in blood glucose) are associated with health complications. Standard tests for diabetes (e.g. random blood sugar and HbA1c) do not test for these excursions despite their association with several health complications. GlycoMark's 1,5-anhydroglucitol (1,5-AG) is a validated indicator of glucose excursions in addition to short-term (1-2 weeks) hyperglycemia. This study is a pre-post, two-round randomized controlled study of a nationally representative sample of primary care physicians. Investigators will assess whether physician participants are able to identify and address glycemic variability and hyperglycemia in their patients and, when given access to GlycoMark assay results, improve their patient management decisions by taking steps to optimize glycemic control, and reduce unnecessary resource utilization.
Study Details
Timeline
Interventions
Online educational materials on GlycoMark 1,5-AG and sample test results for simulated patients
Simulated diabetic patients cared for online